In this study, we investigated the potential role of NRG1/ERBB3/ERBB2 signaling in different clinical and molecular subtypes of breast cancers, by combining metanalysis on patients’ survival and gene expression, and by exploring in vitro potential effects induced by the activation of this pathway. This evidence concerns the gene ERBB2 and breast carcinoma.